CLINICAL TRIALS PROFILE FOR BOSULIF

All Clinical Trials for BOSULIF

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT02228382 ↗	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors	Terminated	Developmental Therapeutics Consortium	Phase 4	2014-11-07	The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors).
NCT02228382 ↗	Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors	Terminated	Pfizer	Phase 4	2014-11-07	The purpose of this study is to fulfill the post-authorization commitment made by Pfizer to the European Medicines Agency in providing additional safety and efficacy data in approximately 150 Philadelphia Chromosome Positive Chronic Myeloid Leukemia patients with high unmet medical need, including 75 Chronic Phase, Accelerated Phase or Blast Phase patients in the fourth or later line treatment setting (i.e., after treatment with at least 3 other Tyrosine Kinase Inhibitors).
NCT02269267 ↗	The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)	Completed	Barbara Ann Karmanos Cancer Institute	Phase 2	2014-12-18	This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗	The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)	Completed	Dana-Farber Cancer Institute	Phase 2	2014-12-18	This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.
NCT02269267 ↗	The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)	Completed	Duke Cancer Institute	Phase 2	2014-12-18	This is a non-randomized, prospective, single-group longitudinal study. The purpose of this study is to improve the decision making process used by physicians and patients when they are considering stopping their Tyrosine Kinase Inhibitor (TKI) medication.

Clinical Trial Conditions for BOSULIF

Condition Name

Condition Name for BOSULIF
Intervention	Trials
Leukemia	3
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	2
Chronic Myelogenous Leukemia	2
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive	1

Condition MeSH

Condition MeSH for BOSULIF
Intervention	Trials
Leukemia, Myeloid	12
Leukemia, Myelogenous, Chronic, BCR-ABL Positive	11
Leukemia	9
Philadelphia Chromosome	3

Clinical Trial Locations for BOSULIF

Trials by Country

Trials by Country for BOSULIF
Location	Trials
United States	90
Italy	11
Spain	4
Austria	2
United Kingdom	2

Trials by US State

Trials by US State for BOSULIF
Location	Trials
Texas	7
California	6
Washington	4
Michigan	4
Florida	4

Clinical Trial Progress for BOSULIF

Clinical Trial Phase

Clinical Trial Phase for BOSULIF
Clinical Trial Phase	Trials
Phase 4	1
Phase 2	7
Phase 1/Phase 2	2

Clinical Trial Status

Clinical Trial Status for BOSULIF
Clinical Trial Phase	Trials
Recruiting	7
Completed	3
Terminated	3

Clinical Trial Sponsors for BOSULIF

Sponsor Name

Sponsor Name for BOSULIF
Sponsor	Trials
Pfizer	10
National Cancer Institute (NCI)	5
M.D. Anderson Cancer Center	3

Sponsor Type

Sponsor Type for BOSULIF
Sponsor	Trials
Other	28
Industry	19
NIH	5

Clinical Trials Update, Market Analysis, and Projection for BOSULIF (Bosutinib)

Last updated: January 29, 2026

Summary

BOSULIF (bosutinib) is a targeted tyrosine kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) in 2017 for the treatment of adult patients with chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy. This report evaluates recent clinical trial developments, market performance, growth prospects, and competitive positioning.

---

1. Clinical Trials Update

Recent Clinical Trials for BOSULIF

Trial ID	Phase	Objective	Status	Key Outcomes	Sponsor
NCT03035440	Phase 2	Long-term efficacy/safety in chronic phase CML	Completed	Demonstrated durable response in resistant/intolerant patients	Pfizer
NCT03415768	Phase 3	BOSULIF vs. Imatinib in newly diagnosed CML	Ongoing	Data pending; expected to clarify positioning in front-line setting	Pfizer
NCT03935145	Phase 2	Bosutinib for pediatric CML	Recruiting	Evaluating safety profile in pediatric subgroup	Pfizer
NCT04305195	Phase 1/2	Combination therapy with other TKIs	Ongoing	Focused on overcoming resistance mechanisms	Pfizer

Key Clinical Insights

• Efficacy in Resistant/Intolerant Populations: Data confirms BOSULIF’s ability to induce major molecular responses (MMR) in resistant cases, with response rates exceeding 50% in some studies.
• Comparison with Other TKIs: BOSULIF maintains a favorable safety profile, especially regarding lower rates of edema, pleural effusion, and cardiovascular events compared to ponatinib and nilotinib.
• Regulatory and Label Updates: U.S. and EU approvals remain consistent; ongoing trials seek to expand indications into pediatric populations and combination treatments.

---

2. Market Analysis

Market Landscape

Parameter	Details
Global CML Market Size (2022)	USD 2.1 billion (estimated)
Key Competitors	Imatinib, dasatinib, nilotinib, ponatinib, asciminib
Market Share (2022)	BOSULIF: Approx. 8-10%, primarily in resistant/intolerant populations
Market Penetration	Limited in front-line setting; higher in second-line and resistant cases

Sales Performance (2022)

Region	Estimated Sales (USD millions)	Growth Rate	Notes
North America	$120	12% YoY	Dominates due to high prescription rate in resistant cases
Europe	$70	8% YoY	Slower uptake; reimbursement hurdles present
Asia-Pacific	$30	15% YoY	Growing market; increasing access in Japan and China
Rest of World	$10	10% YoY	Limited distribution

Key Market Drivers and Constraints

Drivers	Constraints
Rising prevalence of CML	Competition from first-line TKIs (imatinib, dasatinib)
Favorable safety profile	Limited indication scope currently (resistance/ intolerance)
Evolving treatment guidelines	Patent expiry concerns in key markets (2024-2026)
Successful clinical trials expanding indication	Pricing pressures and reimbursement barriers

---

3. Market Projection (2023-2030)

Projection Assumptions

• Steady increase in use for resistant or intolerant CML cases.
• Accelerated adoption if further trials support first-line use.
• Key markets: North America, Europe, Asia-Pacific.
• Competition in the TKIs segment remains intense.

Year	Estimated Market Size (USD billion)	BOSULIF Market Share Projection	Sales Forecast (USD millions)
2023	2.3	10%	$230
2024	2.6	12%	$312
2025	3.0	14%	$420
2026	3.4	15%	$510
2027	3.8	16%	$608
2028	4.2	17%	$714
2029	4.6	18%	$828
2030	5.0	20%	$1,000

Source: Market Research Future (MRFR) and IQVIA estimates

Growth Drivers

• Expansion into front-line therapy pending trial success.
• Combination therapies incorporating BOSULIF.
• Increased awareness and diagnostic capabilities for resistant cases.
• Global expansion, especially in emerging markets.

Risks & Challenges

• Competition from novel agents like asciminib (ABL001).
• Patent expiries approaching in key jurisdictions (2024).
• Potential safety concerns limiting broader use.
• Pricing pressures reducing profit margins.

---

4. Competitive Positioning

Agent	Indication	Strengths	Weaknesses	Status
Bosutinib (BOSULIF)	Resistant, intolerant CML	Favorable safety, oral	Limited front-line data	Approved (2017)
Imatinib	First-line CML	Established efficacy	Resistance issues	Market leader
Dasatinib	Resistant, front-line	High efficacy	Side-effects	Widely used
Nilotinib	Resistant, front-line	Potent, tolerability	Cardiovascular risks	FDA approved
Ponatinib	Resistant/Ph+ CML	Effective in T315I mutations	Thrombotic risks	Approved, high potency
Asciminib (ABL001)	Targeted in development	Novel mechanism	Clinical stage	Expected future competitor

---

5. Regulatory Landscape & Policy Considerations

• FDA & EMA Approvals: BOSULIF approved in 2017 for resistant/intolerant CML.
• Orphan Drug Designations: Not applicable.
• Pricing & Reimbursement: Varies; efforts underway to optimize coverage in emerging markets.
• Market Access Barriers: Reimbursement policies and depth of healthcare infrastructure influence adoption rates.

---

Key Takeaways

• Clinical momentum indicates sustained efficacy of BOSULIF in resistant and intolerant CML, with ongoing trials exploring new indications and combination approaches.
• Market penetration remains concentrated in resistant cases, with substantial growth expected if biomarker-driven strategies increase front-line adoption.
• Competitive landscape is intensifying with the emergence of novel agents such as asciminib, demanding continuous differentiation based on safety and efficacy.
• Sales forecasts suggest a compound annual growth rate (CAGR) of approximately 15% from 2023 through 2030, contingent upon clinical success and regulatory approvals.
• Strategic focus should include expanding indication spectrum, real-world evidence accumulation, and addressing reimbursement challenges to maximize market share.

---

FAQs

1. What are the main therapeutic advantages of BOSULIF over other TKIs?
   BOSULIF exhibits a favorable safety profile with lower incidences of edema, pleural effusion, and cardiovascular events, making it suitable for resistant or intolerant patients who cannot tolerate other TKIs.

2. Can BOSULIF be used as a first-line treatment for CML?
   Currently, BOSULIF is approved primarily for resistant or intolerant cases. Ongoing trials are evaluating its efficacy as a first-line agent; positive results could expand its approved use.

3. What are the primary safety concerns associated with BOSULIF?
   Side effects are generally manageable but include gastrointestinal disturbances, hematologic toxicities, and rare occurrences of liver enzyme elevations. Cardiotoxicity is less frequent compared to ponatinib.

4. How does BOSULIF’s market share compare to other TKIs?
   BOSULIF holds approximately 8-10% of the global CML TKI market, mainly in resistant populations. Its adoption is limited in first-line settings but steadily growing.

5. What is the outlook for BOSULIF’s future in CML treatment?
   With clinical trials promising expanded indications and combination therapies, BOSULIF’s role is likely to grow, especially if it demonstrates comparable or superior efficacy with an improved safety profile.

---

References

1. Pfizer. BOSULIF (bosutinib) prescribing information. 2017.
2. FDA. BOSULIF (bosutinib) approval letter. 2017.
3. IQVIA. Global Oncology Market Reports. 2022.
4. MarketResearchFuture (MRFR). CML Market Analysis and Forecast. 2023.
5. European Medicines Agency (EMA). BOSULIF Summary of Product Characteristics. 2018.